Exelixis' flagship oncology drug Cabometyx has attracted a pharma partner to take it into a new type of cancer thanks to promising results in a pivotal trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,